Researchers in Michael Sigals lab at the Max Delbruck Center and Charite - Universitatsmedizin Berlin have discovered the ...

Vedolizumab (Entyvio) and infliximab (Remicade) led to mostly similar 1-year outcomes in patients with ulcerative colitis ...

The search for effective therapies in ulcerative colitis, a chronic inflammatory condition affecting the colon and rectum ...

A simple, non-invasive treatment focused on the ears could one day provide relief for people with ulcerative colitis, a UM ...

Israel's Teva Pharmaceutical Industries and French drugmaker Sanofi said a study of a drug to treat ulcerative colitis and ...

Topline Clinical Data Demonstrates Activity of SOR102 Across Multiple Clinical Endpoints Supporting Advancement to Phase 2 ...

Teva Pharmaceuticals and Sanofi announced positive results in a Phase 2b trial of their drug for ulcerative colitis and Crohn ...

Upadacitinib may offer superior disease management than tofacitinib for patients with ulcerative colitis. Learn more.

Researchers have uncovered potentially diagnostic gut microbiome signatures and metabolic pathways associated specifically ...

A clinical abstract on the induction results from the CoTikiS Phase 2 trial of anti-IL-7 Receptor Lusvertikimab in Ulcerative ...

Teva and its partner Sanofi say 47.8% of patients with ulcerative colitis who received a high dose of their drug duvakitug experienced clinical remission, compared with 20.5% who received a placebo.

Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease Primary endpoints met in ulcerative colitis (UC) and Crohn’s disease (CD), the most ...